作者
Guoqiang Han,Manman Cui,Pengbo Lu,Tiantian Zhang,Rong Yin,Jin Hu,Jihua Chai,Jing Wang,Kexin Gao,Weidong Liu,Shuxin Yao,Ziyan Cao,Yanbing Zheng,Wen Tian,Rongxia Guo,Min Shen,Zheming Liu,Weiming Li,Shanshan Zhao,Xiangpeng Lin,Yuhui Zhang,Kehan Song,Yan Sun,Fuling Zhou,Haojian Zhang
摘要
Mitochondrial adaptations dynamically reprogram cellular bioenergetics and metabolism and confer key properties for human cancers. However, the selective regulation of these mitochondrial responses remains largely elusive. Here, inspired by a genetic screening in acute myeloid leukemia (AML), we identify RAS effector RREB1 as a translational regulator and uncover a unique translation control system for nuclear-encoded mitochondrial proteins in human cancers. RREB1 deletion reduces mitochondrial activities and succinate metabolism, thereby damaging leukemia stem cell (LSC) function and AML development. Replenishing complex II subunit SDHD rectifies these deficiencies. Notably, inhibition of complex II re-sensitizes AML cells to venetoclax treatment. Mechanistically, a short RREB1 variant binds to a conserved motif in the 3' UTRs and cooperates with elongation factor eEF1A1 to enhance protein translation of nuclear-encoded mitochondrial mRNAs. Overall, our findings reveal a unique translation control mechanism for mitochondrial adaptations in AML pathogenesis and provide a potential strategy for targeting this vulnerability of LSCs.